Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study.
Dulucq S, Rigal-Huguet F, Nicolini FE, Cony-Makhoul P, Escoffre-Barbe M, Gardembas M, Legros L, Rousselot P, Liu J, Rea D, De Mas V, Hayette S, Raynaud S, Lacoste-Roussillon C, Robbesyn F, Klein E, Morisset S, Mahon FX, Etienne G. Dulucq S, et al. Among authors: legros l. Br J Haematol. 2023 Jun;201(6):1116-1124. doi: 10.1111/bjh.18796. Epub 2023 Apr 2. Br J Haematol. 2023. PMID: 37004981
Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?
Avet-Loiseau H, Malard F, Campion L, Magrangeas F, Sebban C, Lioure B, Decaux O, Lamy T, Legros L, Fuzibet JG, Michallet M, Corront B, Lenain P, Hulin C, Mathiot C, Attal M, Facon T, Harousseau JL, Minvielle S, Moreau P; Intergroupe Francophone du Myélome. Avet-Loiseau H, et al. Among authors: legros l. Blood. 2011 Feb 10;117(6):2009-11. doi: 10.1182/blood-2010-07-295105. Epub 2010 Oct 20. Blood. 2011. PMID: 20962323 Free article. Clinical Trial.
[Radiotherapy in primary cerebral lymphoma].
Legros L, Benezery K, Lagrange JL. Legros L, et al. Cancer Radiother. 1999 Mar-Apr;3(2):149-53. doi: 10.1016/S1278-3218(99)80045-6. Cancer Radiother. 1999. PMID: 10230374 Review. French.
Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials.
Guilhot F, Gardembas M, Rousselot P, Tulliez M, Vigier M, Buzyn A, Rigal-Huguet F, Legros L, Michallet M, Berthou C, Najman A, Maloisel F, Mahon FX, Facon T, Berthaud P, Guilhot J; CML French Group. Guilhot F, et al. Among authors: legros l. Semin Hematol. 2003 Apr;40(2 Suppl 2):92-7. doi: 10.1053/shem.2003.50048. Semin Hematol. 2003. PMID: 12783382 Review.
Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.
Gardembas M, Rousselot P, Tulliez M, Vigier M, Buzyn A, Rigal-Huguet F, Legros L, Michallet M, Berthou C, Cheron N, Maloisel F, Mahon FX, Facon T, Berthaud P, Guilhot J, Guilhot F; CML French Group. Gardembas M, et al. Among authors: legros l. Blood. 2003 Dec 15;102(13):4298-305. doi: 10.1182/blood-2003-04-1010. Epub 2003 Aug 21. Blood. 2003. PMID: 12933584 Free article. Clinical Trial.
157 results